Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases?

dc.contributor.author	Ritter, T
dc.date.accessioned	2018-08-24T08:26:17Z
dc.date.available	2018-08-24T08:26:17Z
dc.date.issued	2005-06-01
dc.identifier.citation	Ritter, T (2005). Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases?. British Journal of Ophthalmology 89 (6), 648-649
dc.identifier.issn	0007-1161
dc.identifier.uri	http://hdl.handle.net/10379/9817
dc.description.abstract	Improvements in vectors, promoters, and transgenes have to be accomplished before gene therapy could be considered as an option in cornea gene therapy.
dc.publisher	BMJ
dc.relation.ispartof	British Journal of Ophthalmology
dc.rights	Attribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subject	allograft-rejection
dc.subject	endothelial-cells
dc.subject	survival
dc.subject	graft
dc.subject	transplantation
dc.subject	protein
dc.title	Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases?
dc.type	Article
dc.identifier.doi	10.1136/bjo.2005.065854
dc.local.publishedsource	http://bjo.bmj.com/content/bjophthalmol/89/6/648.full.pdf
nui.item.downloads	0

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland